Press coverage about Mesa Laboratories (NASDAQ:MLAB) has been trending somewhat positive this week, according to Accern Sentiment. Accern identifies negative and positive news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Mesa Laboratories earned a coverage optimism score of 0.03 on Accern’s scale. Accern also assigned news headlines about the medical instruments supplier an impact score of 47.6417525191781 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Mesa Laboratories (MLAB) traded up 0.45% during trading on Friday, reaching $149.32. 18,103 shares of the company’s stock traded hands. Mesa Laboratories has a 1-year low of $109.14 and a 1-year high of $169.81. The firm has a 50 day moving average of $136.71 and a 200 day moving average of $138.57. The firm has a market capitalization of $561.14 million, a PE ratio of 53.67 and a beta of 0.47.

Mesa Laboratories (NASDAQ:MLAB) last issued its quarterly earnings results on Monday, July 31st. The medical instruments supplier reported $0.39 EPS for the quarter, missing analysts’ consensus estimates of $0.56 by ($0.17). The firm had revenue of $22.67 million for the quarter, compared to analysts’ expectations of $22.90 million. Mesa Laboratories had a return on equity of 16.58% and a net margin of 11.31%. Equities analysts forecast that Mesa Laboratories will post $2.74 EPS for the current year.

The company also recently declared a quarterly dividend, which was paid on Friday, September 15th. Stockholders of record on Thursday, August 31st were issued a dividend of $0.16 per share. The ex-dividend date was Tuesday, August 29th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.43%. Mesa Laboratories’s dividend payout ratio (DPR) is presently 22.94%.

Several brokerages recently issued reports on MLAB. TheStreet cut shares of Mesa Laboratories from a “b” rating to a “c+” rating in a research note on Monday, July 31st. Zacks Investment Research raised shares of Mesa Laboratories from a “hold” rating to a “buy” rating and set a $159.00 price objective for the company in a research note on Tuesday, June 13th. Finally, BidaskClub cut shares of Mesa Laboratories from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 12th.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this news story can be viewed at

In other news, Director H Stuart Campbell sold 1,000 shares of Mesa Laboratories stock in a transaction dated Friday, August 4th. The shares were sold at an average price of $143.09, for a total transaction of $143,090.00. Following the completion of the sale, the director now directly owns 47,976 shares in the company, valued at $6,864,885.84. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Over the last quarter, insiders have sold 8,610 shares of company stock valued at $1,176,809. Insiders own 15.70% of the company’s stock.

About Mesa Laboratories

Mesa Laboratories, Inc is focused primarily on quality control products and services. The Company operates through four segments: Instruments, Continuous Monitoring, Biological Indicators and Cold Chain. The Instruments Division designs, manufactures and markets quality control instruments and disposable products.

Insider Buying and Selling by Quarter for Mesa Laboratories (NASDAQ:MLAB)

Receive News & Ratings for Mesa Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.